tiprankstipranks
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

TARS Stock Latest News

Elanco sells royalty, milestone rights for Xdemvy to Blackstone for $295M
The FlyElanco sells royalty, milestone rights for Xdemvy to Blackstone for $295M
9d ago
BX
ELAN
Tarsus Pharmaceuticals’ Earnings Call Highlights Robust Growth
PremiumCompany Announcements
Tarsus Pharmaceuticals’ Earnings Call Highlights Robust Growth
11d ago
TARS
Tarsus Pharmaceuticals: Strong Financial Performance and Strategic Growth Initiatives Drive Buy Rating
PremiumRatings
Tarsus Pharmaceuticals: Strong Financial Performance and Strategic Growth Initiatives Drive Buy Rating
11d ago
TARS
Tarsus Pharmaceuticals price target raised to $84 from $78 at Guggenheim
PremiumThe Fly
Tarsus Pharmaceuticals price target raised to $84 from $78 at Guggenheim
12d ago
TARS
Tarsus Pharmaceuticals Reports Strong Q1 2025 Growth
PremiumCompany Announcements
Tarsus Pharmaceuticals Reports Strong Q1 2025 Growth
12d ago
TARS
Tarsus Pharmaceuticals reports Q1 EPS (64c), consensus (63c)
PremiumThe FlyTarsus Pharmaceuticals reports Q1 EPS (64c), consensus (63c)
12d ago
TARS
Tarsus Pharmaceuticals to present abstracts on XDEMVY at ASCRS meeting
Premium
The Fly
Tarsus Pharmaceuticals to present abstracts on XDEMVY at ASCRS meeting
22d ago
TARS
Tarsus Pharmaceuticals 2.809M share Spot Secondary priced at $44.50
Premium
The Fly
Tarsus Pharmaceuticals 2.809M share Spot Secondary priced at $44.50
2M ago
TARS
Tarsus Pharmaceuticals announces $100M common stock offering
PremiumThe Fly
Tarsus Pharmaceuticals announces $100M common stock offering
2M ago
TARS
Tarsus Pharmaceuticals price target raised to $58 from $54 at Jefferies
PremiumThe Fly
Tarsus Pharmaceuticals price target raised to $58 from $54 at Jefferies
2M ago
TARS
Tarsus Pharmaceuticals’ Earnings Call Highlights Success and Challenges
PremiumCompany Announcements
Tarsus Pharmaceuticals’ Earnings Call Highlights Success and Challenges
3M ago
TARS
Hold Rating for Tarsus Pharmaceuticals Amid Strong Sales and Market Uncertainties
PremiumRatings
Hold Rating for Tarsus Pharmaceuticals Amid Strong Sales and Market Uncertainties
3M ago
TARS
Guggenheim ups Tarsus Pharmaceuticals price target, would buy on weakness
PremiumThe FlyGuggenheim ups Tarsus Pharmaceuticals price target, would buy on weakness
3M ago
TARS
Tarsus Pharmaceuticals: Strong Earnings and Growth Potential Make It a Buy
Premium
Ratings
Tarsus Pharmaceuticals: Strong Earnings and Growth Potential Make It a Buy
3M ago
TARS
Tarsus Pharmaceuticals: Undervalued Growth Potential and Acquisition Appeal Reinforce Buy Rating
Premium
Ratings
Tarsus Pharmaceuticals: Undervalued Growth Potential and Acquisition Appeal Reinforce Buy Rating
3M ago
TARS
Tarsus Pharmaceuticals price target lowered to $60 from $62 at Barclays
PremiumThe Fly
Tarsus Pharmaceuticals price target lowered to $60 from $62 at Barclays
3M ago
TARS
Tarsus Pharmaceuticals Reports Strong 2024 Financial Results
PremiumCompany Announcements
Tarsus Pharmaceuticals Reports Strong 2024 Financial Results
3M ago
TARS
Tarsus Pharmaceuticals price target lowered to $70 from $75 at BofA
PremiumThe Fly
Tarsus Pharmaceuticals price target lowered to $70 from $75 at BofA
3M ago
TARS
Tarsus Pharmaceuticals: Strong Buy Rating Driven by Impressive Financial Performance and Strategic Growth Positioning
PremiumRatings
Tarsus Pharmaceuticals: Strong Buy Rating Driven by Impressive Financial Performance and Strategic Growth Positioning
3M ago
TARS
Tarsus Pharmaceuticals reports Q4 EPS (60c), consensus (82c)
PremiumThe FlyTarsus Pharmaceuticals reports Q4 EPS (60c), consensus (82c)
3M ago
TARS
Strong Growth Prospects and Market Expansion Drive Buy Rating for Tarsus Pharmaceuticals
Premium
Ratings
Strong Growth Prospects and Market Expansion Drive Buy Rating for Tarsus Pharmaceuticals
3M ago
TARS
Tarsus Pharmaceuticals price target raised to $62 from $60 at Barclays
Premium
The Fly
Tarsus Pharmaceuticals price target raised to $62 from $60 at Barclays
4M ago
TARS

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >